Literature DB >> 20480006

Characteristics of lipo-oligosaccharide loci of Campylobacter jejuni isolates associated with Guillain-Barré Syndrome from Hebei, China.

Hai Jiang1, Mao-Jun Zhang, Rui-Chun Liu, Xin-Ying Tian, Yi-Xin Gu, Jian-Zhong Zhang.   

Abstract

Ganglioside mimicry by C.jejuni lipo-oligosaccharides (LOS) could induce the production of autoantibodies against gangliosides and the development of Guillain-Barré syndrome (GBS). The LOS biosynthesis region exhibits significant variation with different strains. Using PCR amplifications of genes from published LOS loci and sequencing the LOS biosynthesis loci, the eight GBS-associated C. jejuni strains from HeBei could be classified into four classes. The expression of sialylated LOS structures (class A) or non-sialylated LOS structures(class F, H and P) in the C. jejuni LOS is considered to be two different factors for the induction of GBS.

Entities:  

Keywords:  Campylobacter jejuni; Guillain-Barré syndrome; lipo-oligosaccharides

Mesh:

Substances:

Year:  2010        PMID: 20480006      PMCID: PMC2869223          DOI: 10.3390/ijms11031155

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


Introduction

Campylobacter jejuni (C. jejuni) is the leading cause of acute bacterial gastroenteritis worldwide. It has been associated with the development of Guillain-Barré syndrome (GBS), a post-infectious polyneuropathy [1-4]. The association between C. jejuni and the development of GBS is thought to result from the molecular mimicry between outer core structures of bacterial lipo-oligosaccharides (LOS) and gangliosides in peripheral nerves [1,2,4-6]. LOS of C. jejuni display considerable variation in the outer core structure. Microarray and PCR probing studies have shown that there is extensive variation in the gene content of the locus [7]. Based on gene content and organization, the loci are divided into eight classes (Class A through H) [8]. Many studies indicate that the Class A locus is predominately associated with GBS [8-10]. A recent study identified 11 new classes of LOS loci that were distinctly different from the previous eight classes [11]. They demonstrated the insertions and deletions of genes were related among different LOS classes. In the present study, the characteristics of loci involved in the biosynthesis of the LOS outer core from eight C. jejuni strains isolated from GBS patients in Hebei, China were studied.

Results and Discussion

Gene Contents and Organizations of the LOS Biosynthesis Loci in 8 C.jejuin Strains

According to the general organization of the LOS biosynthesis genes, the eight C. jejuni strains in this study could be classified into four classes “A,” “F,” “H,” and “P”. Four strains, QYT, LXC, ZHX, and ZB, which have 13 ORFs and only one copy of cgtA gene (orf5) in a 12.2-kb locus, belonged to class A. The 12.2-kb DNA sequences among the four Class A strains had 98% identity. An alignment of the deduced protein sequences of the cstII gene (sialytransferase) from four class A strains gave 96% identity. Three strains (LXC, ZHX and ZB) had mono-functional CstII (Thr51) and strain QYT had bi-functional CstII character with Asn51, Leu-54, and Ile-269. There was also a missing A base at position 1,234 of orf3 in these class A strains which were consisted with previous description [9]. Strain XWM has 9 ORFs in a 8.5-kb locus, and belonged to Class F. It lacks the neuBCA and cst genes and likely directs the synthesis of nonsialylated LOS structures. The DNA sequence of the 8.5-kb LOS of strain XWM showed a 99.7% identity with strain RM1170, and showed 99.3% identity with strain GB15, which were both identified as Class F [11]. Strain LC has 18 ORFs in a 14.8-kb locus, which showed a 99.0% DNA sequence identity to strain RM1047, belonged to Class H. Two strains, LL and ZX, belonged to Class P, which had 19 ORFs in a 15.8-kb locus with 99.8% DNA sequence identity to strain GB4 [8,11].

Discussion

So far, 46 ORFs were found in LOS loci and 19 major LOS classes: A-S, were identified based on gene content and organization of the LOS biosynthesis loci [1]. Classes A, B, and C were involved in sialylated LOS synthesis [9,12-16]. The present study described the LOS characteristics of eight C. jejuni strains isolated from GBS patients from north China. Four of them belonged to Class A, which was consistent with previous reports [8-10,16]. Classes F, H, and P were found in four strains that possessed non-sialylated LOS structure. The presence of these four classes of LOS loci demonstrated genetic rearrangements and the complexity of LOS biosynthesis loci in GBS associated C. jejuni strains. However, no additional experiments have been done on analysing the LOS structure and the gangliosides mimics of each strain. With respect to other non-ganglioside-like structures (class F, H and P) that may be involved in molecular mimicry in the development of GBS. Godschalk et al. have demonstrated that co-infection with multiple C. jejuni strains also occurs in GBS patients [10]. Co-infections with multiple C. jejuni strains might be an alternative explanation to these classes. Although the presence of certain C. jejuni genes involved in sialylated LOS biosynthesis may be crucial for induction of the anti-ganglioside immune response that leads to GBS, the genetic susceptibility of host may also contribute to differences in clinical outcomes of the patients [8,14,20]. Besides the gene content, DNA sequence of this locus from multiple strains indicated that C.jejuni used other mechanisms to vary its outer core: phase variation because of homopolymeric tracts, gene inactivation by the deletion of a single base (without phase variation) and single or multiple mutations leading to allelic glycosyltransferases [9]. Nam Shin et al. have observed that the absence of a β-1,2-glucosyl residue on Hep-II makes possible the sialylation of the inner β-1,3-Gal residue by CstII [18]. Gilbert et al. suggested that the inactivation of the second domain of orf3 by a frameshift mutation is the genetic basis for the absence of a β-1,2-glucosyl residue on Hep-II [9]. In this study, we also found a missing A base at position 1,234 in orf3 among 4 class A strains (QYT, ZB, ZHX, and LX), which might infer the inactivation of the second domain of Orf3 due to frameshift mutation [9]. One of the variable residues among the CstII versions can result in either a mono-functional CstII (Thr51) or a bi-functional CstII (Asn51), so it has been suggested that the expression of different ganglioside-like structures might have an impact on the outcome of the GBS [19]. The alignment of the Cst-II protein sequence verified that only a class A strain (QYT) possessed the residue Asn51. Phase variation using homopolymeric G tracts was responsible for some of the variations in LOS outer core structures [9,11]. It still needs to be determined whether orf23 and orf25 in the class H and P loci might exhibit different enzymatic specificities until the LOS structures for all of these strains are determined. In this study, we found classes H (strain LC) and P (strain LL and ZX) shared similar gene content and organization, besides the deletion–insertion event of orf28 and orf39 with Classes E and H. The orf28 gene was clearly missing in the Class H strain (LC) where orf26 was disrupted by orf39. Indeed, the deletion–insertion event of orf28 between class H and class P resulted in LOS differences, which led to a truncated LOS, as observed by SDS-PAGE (Figure 1). Based on BLAST searches, orf28 was proposed to encode a putative glycosyltransferase and orf39 was proposed to encode a putative butyryltransferase that was involved in the synthesis of the O-antigen of E. coli O91 [17].
Figure 1.

SDS-gels followed by silver staining of LOS extracts from C. jejuni LC (class H) and ZX (class P).

Parker et al demonstrated that most of the GBS-associated strains (12 of 16 GBS strains) were HS:19 or HS:41, and 15 of them belonged to Class A, one belonged to Class C[8]. We found that only C. jejuni ZB and LXC were HS:19 and belonged to Class A. This reflected that the Penner serotype is not determined by the LOS characters.

Materials and Methods

Bacteria Identification and Serotyping

The eight C. jejuni strains were isolated from the stool specimens of eight GBS patients in the Second Hospital of Hebei Medical University in 1993. The isolates were cultured on Columbia agar supplemented with 5% sheep blood under micro-aerophilic conditions (5% O2, 10%CO2, and 85% N2) at 42°C for 24 h. Bacteria colonies were characterized by Gram stain, oxidase, catalase tests, and API Campy identification system test (API, REF 20800). Campylobacter species-specific PCR for C. jejuni, C. coli, C. lari, C. upsaliensis, and C. fetus were performed according to previous reports. The identified C. jejuni isolates were serotyped by the heat-stable (HS) serotyping scheme of Penner and Hennessy using a commercial 25 Penner heat-stable antisera set (Campylobacter Antisera Seiken Set, Denka Seiken Co., Tokyo) previously described. The serotype results are listed in Table 1.
Table 1.

Campylobacter jejuni strains used in this study.

Strain no.Isolated TimeIsolated PlaceSubtype (GBS)Penner type (HS)LOS locus class
LLCj1993HeiBei ProvinceAMAN37P
ZXCj1993HeiBei ProvinceAMAN37P
LCCj1993HeiBei ProvinceAIDPNDH
LXCCj1993HeiBei ProvinceAMAN19A
QYTCj1993HeiBei ProvinceAMAN2A
ZBCj1993HeiBei ProvinceAMAN19A
ZHXCj1993HeiBei ProvinceAMANNDA
XWMCj1993HeiBei ProvinceAMANNDF

Notes: AMAN: acute motor axonal neuropathy; AIDP: acute inflammatory demyelinating polyneuropathy; ND: not determined.

PCR and PCR Products Sequencing

Genomic DNA of each strain was extracted with the DNeasy tissue kit (QIAGEN, USA). For the different size of PCR products, six pairs of primers were used based on the sequences of C. jejuni NCTC 11168 and 81116 LOS loci. The primers in LOS loci are listed in Table 2. PCR products were purified by PCR gel extraction kit (QIAGEN) and cloned in vector pGEM-T. The inserts were sequenced by primer walking with an ABI Prism Big Dye Terminator (v3.1) cycle sequencing ready reaction kit (v5.0).
Table 2.

Primers used in this Study.

Primer no.Primer sequence5′-3′
P1 aAAAGAATACGAATTTGCTAAAGAGG
P2 bATCATAAAAATCACTTGCCAAAACT
P3 bAATTTTCCAAGAGGAGCACATGCAC
P4 bCTATGGTGTAAGTGGGCATTGGGCT
P5 bAAAAGCCCAATGCCCACTTACAC
P6 aTTGCCAAGGTGAAGTTTGAGTAA
P7 cACATATAGACCCCTGAGGTAATTCTTT
P8 cGTTATTATTGCTGGAAATGGACCAAGT

P1P6 used to amplify the LOS biosynthesis loci of C. jejuni XWM, which were located on orf1 and orf13 respectively, as reported previously [9].

P1P2, P3P4 and P5P6 were used to amplify the LOS biosynthesis loci of C. jejuni LL, ZX and LC. P2P3 and P4P5 were located on orf25 and orf30 respectively from strain 81116.

P1P7 and P8P6 were used to amplify the LOS biosynthesis loci of C. jejuni QYT, LX, ZB and ZHX. P7 and P8 were located on orf7 from NCTC11168.

DNA Sequence Alignment and Assigned GenBank Accession Number

The whole DNA sequence of the LOS biosynthesis loci of eight GBS-associated C. jejuni strains were compared with 19 published classes loci (Class A-S) that belonged to ATCC43432(A), ATCC43449(B), NCTC11168(C), LIO87(D), 81116(E), RM1170(F), ATCC43437(G), ATCC43431(H), RM1850(I), RM1508(J), GB24(K), RM3435(L), RM1503(M), RM2095(N), RM3423(O), GB4(P), RM3437(Q), GC149(R), and RM3419(S), which GenBank accession numbers are AF215689, AF401529, AL139077, AF400669, AJ131360, AY434498, AY436358, AF411225, EU404107, EU404104, AY573817, EU404111, EF140720, AY816330, EF143352, AY943308, EU404112, AY962325, and EU404110, respectively. The nucleotide sequences of LOS biosynthesis loci from eight GBS-associated C. jejuni strains were deposited in GenBank and were assigned with the accession numbers as follows: LLCj LOS locus, DQ535890; QYTCj LOS locus, DQ864651; ZXCj LOS locus, DQ535891; ZBCj LOS locus, DQ864653; ZHXCj LOS locus, DQ864652; LCCj LOS locus, DQ535892; LXCCj LOS locus, DQ864650; XWMCj LOS locus, EF176584.

Conclusions

In the present study, the LOS structure of four GBS associated C. jejuni strains from China were identified as class A. Three classes (classes F, H and P) without the genes required for expression of ganglioside mimicry were found in other four GBS associated strains. Co-infections with multiple C. jejuni strains occur in GBS patients might be an alternative explanation to these classes. Further LOS structure analysis would be helpful to explore the mechanism of C. jejuni associated GBS.
  20 in total

1.  Lipo-oligosaccharides of Campylobacter jejuni serotype O:10. Structures of core oligosaccharide regions from a bacterial isolate from a patient with the Miller-Fisher syndrome and from the serotype reference strain.

Authors:  J E Shin; S Ackloo; A S Mainkar; M A Monteiro; H Pang; J L Penner; G O Aspinall
Journal:  Carbohydr Res       Date:  1997-12       Impact factor: 2.104

2.  Molecular mimicry in Campylobacter jejuni lipopolysaccharides and the development of Guillain-Barré syndrome.

Authors:  A P Moran; M M Prendergast
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

3.  The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core oligosaccharide.

Authors:  Michel Gilbert; Marie-France Karwaski; Stéphane Bernatchez; N Martin Young; Eduardo Taboada; Joseph Michniewicz; Anna-Maria Cunningham; Warren W Wakarchuk
Journal:  J Biol Chem       Date:  2001-10-31       Impact factor: 5.157

4.  Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits.

Authors:  C W Ang; M A De Klerk; H P Endtz; B C Jacobs; J D Laman; F G van der Meché; P A van Doorn
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

5.  Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome.

Authors:  M Koga; M Takahashi; M Masuda; K Hirata; N Yuki
Journal:  Neurology       Date:  2005-09-14       Impact factor: 9.910

6.  Ganglioside-like epitopes of lipopolysaccharides from Campylobacter jejuni (PEN 19) in three isolates from patients with Guillain-Barré syndrome.

Authors:  N Yuki; S Handa; T Tai; M Takahashi; K Saito; Y Tsujino; T Taki
Journal:  J Neurol Sci       Date:  1995-05       Impact factor: 3.181

7.  Comparison of Campylobacter jejuni isolates implicated in Guillain-Barré syndrome and strains that cause enteritis by a DNA microarray.

Authors:  Edward E Leonard; Lucy S Tompkins; Stanley Falkow; Irving Nachamkin
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

8.  Characterization of lipooligosaccharide-biosynthetic loci of Campylobacter jejuni reveals new lipooligosaccharide classes: evidence of mosaic organizations.

Authors:  Craig T Parker; Michel Gilbert; Nobuhiro Yuki; Hubert P Endtz; Robert E Mandrell
Journal:  J Bacteriol       Date:  2008-06-13       Impact factor: 3.490

Review 9.  Campylobacter species and Guillain-Barré syndrome.

Authors:  I Nachamkin; B M Allos; T Ho
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

10.  Ganglioside mimicry of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity in rabbits.

Authors:  C W Ang; P G Noordzij; M A de Klerk; H P Endtz; P A van Doorn; J D Laman
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more
  3 in total

Review 1.  Axonal variants of Guillain-Barré syndrome: an update.

Authors:  Pei Shang; Mingqin Zhu; Ying Wang; Xiangyu Zheng; Xiujuan Wu; Jie Zhu; Jiachun Feng; Hong-Liang Zhang
Journal:  J Neurol       Date:  2020-03-05       Impact factor: 4.849

2.  Molecular and in silico typing of the lipooligosaccharide biosynthesis gene cluster in Campylobacter jejuni and Campylobacter coli.

Authors:  Amber Hameed; Julian M Ketley; Alexandra Woodacre; Lee R Machado; Gemma L Marsden
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

Review 3.  Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored.

Authors:  Ying Wang; Shuang Sun; Jie Zhu; Li Cui; Hong-Liang Zhang
Journal:  Mediators Inflamm       Date:  2015-09-16       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.